tirzepatide for psoriatic arthritis The potential role of GLP-1 receptor agonists in the management of disease: a scoping review | Inflammation Research PsoriasisNews: @Eli Lilly reported positive

However, the dual glucose-dependent insulinotropic polypeptide receptor (GIPR)/GLP-1R agonist, tirzepatide, has demonstrated superior efficacy regarding improvements in HbA 1c and body weight in people with type 2 diabetes

A lower-cost option might lack the comprehensive medical supervision and support critical for safe, sustainable results

Research demonstrates that most gastrointestinal side effects decrease over time as the body adjusts to the medication

Ankylosing spondylitis is a chronic (long-term) condition

(Source: Heally, June 2026) Semaglutide Prescription Shift: Obesity Up 8%, Diabetes Down 6.4% Between March 2025 and June 2025, semaglutide prescriptions for treating diabetes decreased by 6.4% while prescriptions for obesity treatment increased by 8% in the same period